Abstract
Our study implies that cell-free fat extract supplementation can promote embryo development and clinical outcomes and may serve as a rescue strategy for older women with in vitro fertilization failure.
Introduction
As maternal age increases, particularly beyond 35, the success rates of in vitro fertilization (IVF) decline sharply. This decline is primarily attributed to deteriorating embryo quality. While standard synthetic culture media are designed to support early development, they often lack the complex milieu of growth factors and cytokines present in the natural female reproductive tract. This "sterile" environment can exacerbate oxidative stress and lead to developmental delays.
To address this, researchers investigated the potential of cell-free fat extract (CEFFE)—a protein-rich liquid derived from human adipose tissue—as a supplement. CEFFE is known for its antioxidant, anti-aging, and pro-proliferative properties. This study explores whether CEFFE can act as a "rescue strategy" to improve implantation and clinical pregnancy rates in older women with a history of IVF failure.
Methods
The research utilized a translational framework, progressing from animal models to human clinical trials.
Animal and In Vitro Models
Naturally aging mice (10 months old) served as a model for reproductive challenges in older women. Researchers tested CEFFE concentrations of 1%, 2%, and 5% to identify the optimal dosage. Embryo development was monitored using "EmbryoScope" time-lapse technology to track morphokinetic events such as cleavage and blastocyst formation. Additionally, an in vitro implantation model co-cultured mouse blastocysts with human endometrial epithelial cells (HEECs) to evaluate adhesion and invasion capabilities.
Culture Medium Analysis
To ensure the stability and safety of the supplemented media, the team performed a comprehensive analysis of the culture environment, focusing on growth factor profiles and physical properties.
Clinical Trial
A prospective open-label study involved 56 women (age ≥35) with previous IVF failures. The study used two control methods:
- Sibling-Oocyte Split: For patients with at least six oocytes, half were cultured in standard media and half in 2% CEFFE-supplemented media.
- Self-Control: For patients with fewer than six oocytes, outcomes were compared against their own previous unsuccessful cycles.
Safety was a priority; preimplantation genetic testing for aneuploidy (PGT-A) was conducted to confirm that CEFFE did not induce chromosomal abnormalities.
Results
Optimal Concentration and Developmental Speed
The study identified 2% CEFFE as the "sweet spot." While beneficial at lower doses, a 5% concentration tended to decrease developmental rates, likely due to shifts in osmolarity or pH. In young mice, CEFFE supplementation accelerated development, with embryos reaching the 2-cell and morula stages significantly faster than controls.
Rescue of Aged Embryos
In embryos from aged mice, CEFFE significantly reduced apoptosis (programmed cell death), suggesting a protective effect against oxidative stress. Furthermore, the extract enhanced the "stickiness" of embryos, improving their ability to adhere to and invade endometrial cells—a critical step for successful implantation.
Human Clinical Outcomes
The clinical results were striking:
- Embryo Quality: In the sibling-oocyte split group, the 2% CEFFE group showed a significantly higher rate of high-quality Day 3 embryos (33.33% vs. 19.51%, P=0.045).
- Implantation and Pregnancy: Implantation rates more than doubled (51.85% vs. 22.22%, P=0.024), and clinical pregnancy rates jumped from 28.57% to 59.09% (P=0.044).
- Safety: PGT-A confirmed no increase in chromosomal aneuploidy. Among the seven live births in the CEFFE group, no neonatal complications or congenital anomalies were observed.
Discussion
CEFFE appears to bridge the gap between synthetic media and the natural reproductive environment by providing a complex cocktail of over 1,700 proteins, including FGF-2, EGF, and VEGF. By reducing apoptosis and accelerating morphokinetics, it offers a viable path forward for patients who have previously struggled with poor embryo quality.
Limitations and Future Directions
While promising, the study's clinical cohort was small (56 patients). Larger, multi-center randomized controlled trials are necessary to validate these findings. Furthermore, the specific "active" proteins within the 1,700+ identified in CEFFE remain unknown. Future research should focus on isolating these functional components and exploring the epigenetic impacts of supplementation on the developing embryo. Long-term follow-up of children born via CEFFE-assisted cycles is also essential to ensure lifelong safety.
Summary updated